In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).
Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Risperidone | Tranylcypromine may increase the hypotensive activities of Risperidone. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Tranylcypromine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Magnesium sulfate | The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Tranylcypromine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Orphenadrine | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine. |
| Pramipexole | Tranylcypromine may increase the sedative activities of Pramipexole. |
| Rotigotine | Tranylcypromine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine. |
| Sodium oxybate | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Yohimbine. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Tranylcypromine. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Tranylcypromine. |
| Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Tranylcypromine. |
| Desmopressin | The risk or severity of hypertension can be increased when Desmopressin is combined with Tranylcypromine. |
| Icosapent | The risk or severity of hypertension can be increased when Icosapent is combined with Tranylcypromine. |
| Mesalazine | The risk or severity of hypertension can be increased when Mesalazine is combined with Tranylcypromine. |
| Tolmetin | The risk or severity of hypertension can be increased when Tolmetin is combined with Tranylcypromine. |
| Fenoprofen | The risk or severity of hypertension can be increased when Fenoprofen is combined with Tranylcypromine. |
| Sulindac | The risk or severity of hypertension can be increased when Sulindac is combined with Tranylcypromine. |
| Sulfasalazine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Sulfasalazine. |
| Carprofen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Carprofen. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Phenmetrazine. |
| Diflunisal | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Diflunisal. |
| Meclofenamic acid | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Meclofenamic acid. |
| Oxaprozin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxaprozin. |
| Balsalazide | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Balsalazide. |
| Ephedrine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ephedrine. |
| Magnesium salicylate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Magnesium salicylate. |
| Salsalate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salsalate. |
| Choline magnesium trisalicylate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Choline magnesium trisalicylate. |
| Antrafenine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Antrafenine. |
| Tiaprofenic acid | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tiaprofenic acid. |
| Epicaptopril | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Epicaptopril. |
| Taxifolin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Taxifolin. |
| Oxyphenbutazone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxyphenbutazone. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when Tranylcypromine is combined with 1-benzylimidazole. |
| Benoxaprofen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Benoxaprofen. |
| Metamizole | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Metamizole. |
| Cimicoxib | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Cimicoxib. |
| Amibegron | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Amibegron. |
| Solabegron | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Solabegron. |
| Saralasin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Saralasin. |
| Azapropazone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Azapropazone. |
| Salicylamide | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salicylamide. |
| Tyramine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tyramine. |
| Adrafinil | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Adrafinil. |
| Kebuzone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Kebuzone. |
| Isoxicam | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Isoxicam. |
| Indoprofen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Indoprofen. |
| Ibuproxam | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ibuproxam. |
| Floctafenine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Floctafenine. |
| Fenbufen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fenbufen. |
| Etofenamate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Etofenamate. |
| Etilefrine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Etilefrine. |
| Epirizole | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Epirizole. |
| Benzydamine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Benzydamine. |
| Synephrine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Synephrine. |
| Moxisylyte | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Moxisylyte. |
| Dexketoprofen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dexketoprofen. |
| Droxicam | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Droxicam. |
| Firocoxib | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Firocoxib. |
| Clonixin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Clonixin. |
| Morniflumate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Morniflumate. |
| Talniflumate | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Talniflumate. |
| DL-Methylephedrine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with DL-Methylephedrine. |
| Amitraz | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Amitraz. |
| Robenacoxib | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Robenacoxib. |
| Tepoxalin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tepoxalin. |
| Atipamezole | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Atipamezole. |
| Flunixin | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Flunixin. |
| Ractopamine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ractopamine. |
| Tulobuterol | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tulobuterol. |
| Dopexamine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dopexamine. |
| Idazoxan | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Idazoxan. |
| Ebselen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ebselen. |
| Higenamine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Higenamine. |
| Reproterol | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Reproterol. |
| Tinoridine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tinoridine. |
| Tramazoline | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tramazoline. |
| Alclofenac | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Alclofenac. |
| Fentiazac | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fentiazac. |
| Suxibuzone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Suxibuzone. |
| Octopamine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Octopamine. |
| Bumadizone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Bumadizone. |
| Alminoprofen | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Alminoprofen. |
| Fenozolone | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fenozolone. |
| Difenpiramide | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Difenpiramide. |
| Norfenefrine | The risk or severity of hypertension can be increased when Tranylcypromine is combined with Norfenefrine. |